Related Experiment Video
Updated: Jun 13, 2025
08:15
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
518
Perindopril and losartan affect ACE-2 and IL- 6 expression in obese rat model
Andrianto Andrianto1,2, Hanestya O Hermawan1,2, Primasitha M Harsoyo1,2
1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Narra J
|September 16, 2024
Summary
Obesity increases cardiovascular disease risk. This study found losartan and perindopril reduced pro-inflammatory IL-6 but increased ACE2 levels in obese rat adipose tissue.
Area of Science:
- Endocrinology
- Cardiovascular Research
- Pharmacology
Background:
- Obesity is a global health issue linked to cardiovascular diseases.
- Adipocytes express angiotensin-converting enzyme 2 receptors (ACE2) and adipocytokines, potentially triggering cytokine storms.
- Elevated interleukin-6 (IL-6) is associated with inflammation and cardiovascular complications.
Purpose of the Study:
- To investigate the effects of perindopril and losartan on ACE2 and IL-6 levels in adipose tissue of obese rats.
- To assess the potential of these drugs in modulating inflammation and ACE2 expression in obesity-related cardiovascular risk.
Main Methods:
- An in vivo true experimental design with a post-test-only control group was employed.
- Twenty-four male albino rats were divided into non-obese (control), obese (untreated), obese treated with perindopril, and obese treated with losartan groups.
- ACE2 and IL-6 levels in visceral fat tissue were quantified using enzyme-linked immunosorbent assay (ELISA) after 4 weeks of treatment.
Main Results:
- Losartan significantly increased ACE2 levels in obese rats compared to perindopril and untreated obese controls (p=0.011 and p=0.004, respectively).
- Both perindopril and losartan significantly reduced IL-6 levels in obese rats compared to the untreated obese group (p=0.020 and p=0.002, respectively).
Conclusions:
- Perindopril and losartan demonstrate potential in managing obesity-related cardiovascular risks.
- These drugs may suppress pro-inflammatory markers like IL-6 while enhancing protective ACE2 levels in adipose tissue.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
500
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:25Antihypertensive Drugs: Direct Renin Inhibitors
510
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510